[Results of clinical trials of calcium bucloxate (804 CB) in rheumatology].
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000150:complications; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001219:Aspartate Aminotransferases / Q000097:blood; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007651:Keto Acids / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000627:therapeutic use; D010654:Phenylbutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D012216:Rheumatic Diseases / Q000188:drug therapy; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D003510:Cyclohexanes; D007651:Keto Acids; D010654:Phenylbutyrates; D010919:Placebos; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D010653:Phenylbutazone; D007213:Indomethacin
Résultats d'essais cliniques du bucloxate de calcium (804 CB) en rhumatologie